Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

PTC Therapeutics on Monday announced a global licensing and collaboration agreement with Novartis (NVS) for its Huntington’s Disease program, PTC518, under which PTC will receive $1B at closing and is ...

Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.

Shares of PTC Therapeutics Inc. climbed nearly 1% pre-market Tuesday, poised to extend their rally to levels last seen in ...

BofA analyst Tazeen Ahmad raised the firm’s price target on PTC Therapeutics (PTCT) to $41 from $31 and keeps an Underperform rating on the ...

Baird analyst Joel Beatty raised the firm’s price target on PTC Therapeutics (PTCT) to $70 from $52 and keeps an Outperform rating on the ...

Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.

FDA’S DAY AT SCOTUS — Don’t expect the Supreme Court to take a sledgehammer to the FDA’s ability to regulate tobacco.

A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...

Beta-blocker drugs -- commonly used to treat heart and blood pressure issues -- may slow the progression of Huntington's disease (HD), according to a new study.

Yet at the annual meeting of the Menopause Society earlier this fall, researchers presented new evidence that hormone therapy ...